ArticleNeuropsychiatric disease and treatment2017
The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study.
Article in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 88 citations in OpenAlex.
- Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Trial
- Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.Addiction (Abingdon, England) · 2022Trial
- Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2018Trial
- Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services.BMC health services research · 2018Trial
- Health-related quality of life measures as predictors for recurrent hospitalization and mortality among patients in heroin-assisted treatment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.Drug and alcohol dependence · 2025Observational
- A tutorial on the what, why, and how of Bayesian analysis: Estimating mood and anxiety disorder prevalence using a Canadian data linkage study.PLOS mental health · 2025Article
- Article
- Immediate Effects of Mindful Awareness in Body-Oriented Therapy as an Adjunct to Medication for Opioid Use Disorder.Mindfulness · 2024Article
- Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative study.medRxiv : the preprint server for health sciences · 2024Article
- Immediate Effects of Mindful Awareness in Body-oriented Therapy as an Adjunct to Medication for Opioid Use Disorder.Research square · 2024Article
- Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment.Exploratory research in clinical and social pharmacy · 2023Article
- Investigating social deprivation and comorbid mental health diagnosis as predictors of treatment access among patients with an opioid use disorder using substance use services: a prospective cohort study.Substance abuse treatment, prevention, and policy · 2023Article
- Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances.Drug and alcohol dependence · 2023Article
- Erythrocytic Reduced/Oxidized Glutathione and Serum Thiol/Disulfide Homeostasis in Patients with Opioid Use Disorder.Psychiatry and clinical psychopharmacology · 2023Article
- Exploring potential moderators of depressive symptoms and treatment outcomes among patients with opioid use disorder.Addictive behaviors · 2023Article
- Cessation of self-reported opioid use and impacts on co-occurring health conditions.Drug and alcohol dependence · 2023Article
- Article
- Genetics of cannabis use in opioid use disorder: A genome-wide association and polygenic risk score study.PloS one · 2023Article
- Comparison of Psychopathologic Characteristics between Individuals Undergoing Methadone Maintenance Treatment, Opioid Dependents, and Control Group.Addiction & health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is a significant interindividual variability in treatment outcomes in methadone maintenance treatment (MMT) for opioid use disorder (OUD). This prospective cohort study examines the impact of comorbid psychiatric disorders on continued illicit opioid use in patients receiving MMT for OUD.
methodsData were collected from 935 patients receiving MMT in outpatient clinics between June 2011 and June 2015. Using linear regression analysis, we evaluated the impact of having a comorbid psychiatric disorder on continued illicit opioid use during MMT, adjusting for important confounders. The main outcome measure was percentage of opioid-positive urine screens for 6 months. We conducted a subgroup analysis to determine the influence of specific comorbid psychiatric disorders, including substance use disorders, on continued illicit opioid use.
resultsApproximately 80% of participants had at least one comorbid psychiatric disorder in addition to OUD, and 42% of participants had a comorbid substance use disorder. There was no significant association between having a psychiatric comorbidity and continuing opioid use (
conclusionResults from our study may serve to guide future MMT guidelines. Specifically, we find that cocaine or tranquilizer use disorder, comorbid with OUD, places patients at high risk for poor MMT outcomes. Treatment centers may choose to gear more intensive therapy toward such populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.